|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Aprepitant versus dexam-ethasone for preventing chemotherapy-induced delayed emesis inpatients with breast cancer : a randomized double-blind study 显示文摘 | Roila F Ruggeri B Ballatori E | 2014 | J Clin Oncol2014，32，2： | 1 |
| 2 | The impact of chemotherapy - induced nausea and vomiting on health - re- lated quality of life显示文摘 | Ballatori E Roila F Ruggeri B | 2007 | Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer2007，15，2： | 1 |
| 3 | The impact ofchemotherapy - in- duced nausea and vomiting on health related quality of life 显示文摘 | Ballatori E Roila F Ruggeri B | 2007 | Supportive Care in Cancer2007，15，2： | 1 |
| 4 | Osteosarcoma:prognosis plateau warrants retinoblastoma pathway targeted therapy显示文摘Osteosarcoma(OS)is the most common primary bone cancer in children and adolescents,affecting~560 young patients in the United States annually.The term OS describes a diverse array of subtypes with varying prognoses,but the majority of tumors are high grade and aggressive.Perhaps because the true etiology of these aggressive tumors remains unknown,advances in OS treatment have reached a discouraging plateau,with only incremental improvements over the past 40 years.Thus,research surrounding the pathogenesis of OS is essential,as it promises to unveil novel therapeutic targets that can attack tumor cells with greater specificity and lower toxicity.Among the candidate molecular targets in OS,the retinoblastoma(RB)pathway demonstrates the highest frequency of inactivation and thus represents a particularly promising avenue for molecular targeted therapy.This review examines the present thinking and practices in OS treatment and specifically highlights the relevance of the RB pathway in osteosarcomagenesis.Through further investigation into RB pathway-related novel therapeutic targets,we believe that a near-term breakthrough in improved OS prognosis is possible. | Sarah E Ballatori Philip W Hinds | 2016 | Signal Transduction and Targeted Therapy2016，1，1： | 1 |
| 5 | The impact of chemotherapyinduced nausea and vomiting on health-related quality of life显示文摘 | Ballatori E Roila F Ruggeri B | 2007 | Support Care Cancer2007，15，： | 1 |
| 6 | Improving information to Italian cancer patients:results of a randomized study显示文摘 | De Lorenzo F Ballatori E Di Costanzo F | 2004 | Ann Oncol2004，5，5： | 1 |
| 7 | The impact of chemother- apy-induced nausea and vomiting on health--related quality of life显示文摘 | Ballatori E Roila F Ruggeri B | 2007 | Supportive Care in Cancer2007，15，2： | 1 |
| 8 | 5-HT3 receptor antagonists:differences and similarities显示文摘 | Roila F Ballatori E Tonato M | 1997 | Eur J Cancer1997，33，9： | 1 |
| 9 | Methodology of drug utilization studies显示文摘 | E Ballatori F Roila and B Ruggeri | 2004 | Suppl Tumori2004，3，4： | 1 |
| 10 | The impact of chemotherapy-in-duced anemia and vomiting on health-related quality of life显示文摘 | Ballatori E Roila F Ruggeri B | 2007 | SupportCare Cancer2007，15，2： | 1 |
| 11 | Aprepitant versus dexam-ethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study显示文摘 | Roila F Ruggeri B Ballatori E | 2014 | J Clin Oncol2014，32，2： | 1 |
| 12 | The impact of chemotherapy- induced nausea and vomiting on health-relatedquality of life 显示文摘 | Ballatori E Roila F Ruggeri B | 2007 | Support Care Cancer2007，15，2： | 1 |
| 13 | Guidelines for the control of nausea and vomiting with chemotherapy of low or minimal emetic potential 显示文摘 | Olver I Clark-Snow R A Ballatori E | 2011 | Support Care Cancer2011，19，1： | 1 |
| 14 | The efficacy and cost-effectiveness of various antiemetic regimens显示文摘 | Roila F Ballatori E | 1998 | Curr Opin Oncol1998，10，4： | 1 |
| 15 | The efficacy and cost2effectiveness of various anlicmetic regimens显示文摘 | Roila F Ballatori E | 1998 | Curr Opin Oncol1998，10，4： | 1 |
| 16 | Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy显示文摘 | Ballatori E Roila F | 2003 | Health Qual Life Outcomes2003，1，1： | 1 |
| 17 | Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer:a randomized double-blind study显示文摘 | Roila F Ruggeri B Ballatori E | 2014 | J Clin Oncol2014，32，： | 1 |
| 18 | The impact of chemotherapy-induced nausea and vomiting on health-related quality of life显示文摘 | Ballatori E Roila F Ruggeri B | 2007 | Supportive Care in Cancer2007，15，2： | 1 |
| 19 | Aprepitant versus metoclopramide,both combined with dexamethasone,for the prevention of cisplatin-induced delayed emesis:a randomized,double-blind study显示文摘 | Roila F Ruggeri B Ballatori E | 2015 | Ann Oncol2015，26，： | 1 |
| 20 | Aprepitant versus dexam- ethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study显示文摘 | Roila F Ruggeri B Ballatori E | 2014 | J Clin Oncol2014，32，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员